Researchers studied 1,866 postmenopausal women and found that using bisphosphonate for more than one year helped reduce the risk of colorectal cancer by 59 percent. The bisphosphonate used by a majority of women was alendronate, sold under the brand name Fosamax and made available under a generic brand. The positive effect of taking bisphosphonate after the one-year mark was not as significant, according to the report.
Read the news report about bisphosphonate and CRC.
Read other coverage about colorectal cancer:
– 10 Recent Findings on GI Quality Issues
– Pricetag of Treating CRC: $14.1B
– USPSTF Advises Against CRC Screening for Individuals Older Than 85
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
